Navigation Links
Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
Date:8/13/2009

PITTSBURGH, Aug. 13 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has released its official and final report regarding the agency's review of allegations made in a July newspaper article concerning the company's Morgantown, W.Va., manufacturing facility. The newspaper article, which included unfounded and highly inaccurate allegations, was based on improperly obtained documents, uninformed third-party commentary and anonymous sources. The final FDA report closes the inspection with no deficiencies found and no FDA "483" issued.

Mylan Chairman and CEO Robert J. Coury said: "I would like to thank the FDA for thoroughly reviewing this matter. The baseless speculation that was caused by a highly irresponsible and sensational newspaper article with a biased agenda was entirely unnecessary. Our customers and stakeholders recognize that there is no one in a better position to speak about issues such as these than a company's senior management or the applicable regulatory agency. It would be a mistake for anyone to rely on uninformed sources.

"Mylan's manufacturing facilities -- especially our plant in Morgantown -- have always represented the gold standard when it comes to quality. Without ever getting complacent, our entire management team and all of our employees continue to demonstrate an unyielding commitment to sustain the highest of quality standards. I would like to thank all of our employees for their continued hard work and execution, and I am pleased that this investigation is formally behind us."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
2. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
3. Mylan Announces Enhancements to Executive Management Team
4. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
5. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
6. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
9. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: